<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[GoLiver Therapeutics 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=35405></link><description><![CDATA[GoLiver Therapeutics 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 04:16:22 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/06/12_3554238800_20200629114727_3748348468.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[GoLiver Therapeutics Receives a Positive Scientific Advice from the European Medicines Agency (EMA) on its Clinical Development and Biomanufacturing Strategy for Acute Liver Failure]]></title><link>https://www.newswire.co.kr/newsRead.php?no=907023</link><description><![CDATA[NANTES, France--(Business Wire/Korea Newswire)--GoLiver Therapeutics, a start-up focused on the development of Innovative Therapy Medicines, in particular cell therapy products for life-threatening liver diseases without the need for transplant using differentiated pluripotent stem cells, announces that the European Medicines Agency (EMA) has given a positive scientific advice on its clinical...]]></description><pubDate>Tue, 30 Jun 2020 09:00:00 +0900</pubDate></item><item><title><![CDATA[고리버 쎄라퓨틱스, 급성 간부전 위한 임상 개발 및 바이오 제조 전략에 대해 유럽의약품청의 긍정적인 과학적 자문받아]]></title><link>https://www.newswire.co.kr/newsRead.php?no=907024</link><description><![CDATA[낭트, 프랑스--(Business Wire/뉴스와이어)--고리버 쎄라퓨틱스(GoLiver Therapeutics)가 유럽의약품청(EMA)으로부터 임상 개발, 약리 독성 및 제품 전략 계획에 대해 긍정적인 과학적 자문을 획득했다고 발표했다.  고리버 쎄라퓨틱스는 혁신치료의약품(Innovative Therapy Medicines) 개발에 주력하는 스타트업으로 특히 차별화된 만능줄기세포를 활용해 치명적 간 질환을 겨냥한 세포치료 제품을 개발하고 있다. 고...]]></description><pubDate>Tue, 30 Jun 2020 09:00:00 +0900</pubDate></item></channel></rss>